A new world beckons for the listed medical cannabis stocks, but liberalisation is not what it seems Tim Boreham Independent Investment Research
The New Criterion: all the dope on Emerald Clinics’ limp debut Tim Boreham Independent Investment Research
The New Criterion: the emerging winners in ‘cannabis corner’ Tim Boreham Independent Investment Research
The New Criterion: pot plays mull over their strategies as sector goes off the boil Tim Boreham Independent Investment Research
The New Criterion: investors rush veterinary cannabis listing Tim Boreham Independent Investment Research
